Commercial Insight: HIV

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2005-08-03

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Despite accounting for only 1% of global pharmaceutical sales, HIV antiretrovirals have experienced rapid growth between 2000-2004, accounting for $6.6 billion in global sales. Enthusiasm for new once daily FDCs and PIs such as Reyataz has rendered the market for first-line naïve patients a battleground where simplicity wins. Even older flagship products such as Combivir are now under threat.


Scope

  • Examination of drivers and resistors to prescription of new FDCs - pricing analysis and opinion leader perception of short and long term toxicities
  • Coverage of FDA approval of Boehringer Ingelheim's Aptivus (tipranavir) - future lessons for clinical studies in highly treatment experienced patients
  • Assessment of the impact of generic antiretrovirals - case analysis of generic didanosine, FDA tentative approval of NNRTIs, efavirenz and nevirapine
  • In-depth regional sales forecasts of marketed and pipeline drugs from 2005 to 2015 with full event analysis


    • Report Highlights
    Datamonitor opinion leader research has revealed that in the majority of Western markets the major route of HIV transmission is changing. Most reported increased presentation of individuals believed to have been infected by heterosexual contact. In countries such as France, immigrants from Sub-Saharan Africa continue to dominate new diagnoses.

    In 2004, the global market for HIV antiretrovirals was valued at $6.6 billion with the US accounting for around 70% of value. In Europe, France is the largest market valued at around $600m. Despite an increase in commercial value, most markets apart from the UK have experienced a decline in standard unit volume driven by uptake of FDC products.

    Boehringer Ingelheim's FDA approval for Aptivus (tipranavir) raises the PI class to nine members. Despite challenges during clinical development, testing in a highly experienced population and 24-weeks data using a surrogate for efficacy, tipranavir's approval signals a high need for additional agents to Fuzeon (enfuvirtide) in this patient group.


    Reasons to Purchase

  • Assess the value and volume dynamics of HIV antiretrovirals on a regional level with a 5 year retrospective view
  • Understand the pending impact of patent expiries and generic incursion on the antiretrovirals market, including product-specific case studies
  • Obtain full global, country, class and product-specific forecasts of currently marketed and pipeline antiretrovirals from 2005 to 2015

    • Table of Contents

    Other users found this report page using the following search terms: hiv ccr5 integrase haart market hiv size share sales date antiretroviral us discovery expiry

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.